Carl Zeiss Meditec: Hitting The Bottom

Carl Zeiss Meditec is rated a Strong Buy with a €75/share price target, implying significant upside after a 60% share price decline. The thesis cites weak China demand, an unfavorable product mix, and FX headwinds, but says core expenses are stable, non-China APAC trends are positive, and bankruptcy risk is minimal. The analyst also expects AEPS to reach €2.4/share by 2028-2029 despite no formal guidance.

Analysis

The market is likely conflating cyclical demand weakness with a permanent impairment of franchise value. In med-tech, China slowdowns often create the best entry points because distributors de-stock first, then hospital procurement normalizes with a lag; that means the next two quarters can still look ugly even if the trough in end demand is already in place. The key second-order effect is that stable operating expense against falling revenue can create visible margin leverage once volumes stabilize, so the earnings inflection can be sharper than consensus expects.

The more important read-through is competitive: if non-China APAC remains resilient, that suggests the company is still taking share in adjacent markets while smaller regional players may be forced to cut pricing to defend volume. That dynamic can also pressure global peers with heavier China exposure, especially if they rely on premium capital equipment cycles rather than recurring consumables/service mix. In that scenario, the market may be underestimating how much of the current drawdown is a multiple compression story rather than a terminal earnings reset.

The main risk is not bankruptcy; it is time. If China weakness persists for another 3-4 quarters, investors will keep capitalizing near-term earnings at distressed multiples, and the stock can stay cheap even if the long-term thesis is intact. The contrarian angle is that the absence of guidance may actually be a positive setup: management has avoided resetting expectations lower, leaving room for a beat as FX and mix normalize and as APAC strength becomes visible in reported numbers.

For long-only holders, the right framework is to treat this as a delayed mean-reversion trade with a 12-24 month horizon, not a quick rebound. The estimate for mid-to-high single-digit earnings power by 2028-2029 implies the market is paying a very low price for optionality on a normalized operating environment, particularly if the company can preserve pricing discipline and avoid an arms race on promotional spend.

Key Decisions for Investors

• Buy the stock on weakness over the next 2-6 weeks, using staged entries rather than all at once; risk/reward improves if the market is still pricing a prolonged China trough and ignores APAC stabilization.
• For portfolios that can use options, express the view via long-dated calls or call spreads with 12-18 month maturity; this captures the earnings inflection without paying full delta for near-term uncertainty.
• Pair trade: long Carl Zeiss Meditec vs short a more China-exposed med-tech peer or broader European healthcare equipment basket; the relative-value case is that stable costs and non-China APAC resilience should show up faster here.
• If you need tighter risk control, wait for any post-results drawdown or guidance-related selloff and initiate there; the best entry is likely after the next quarter confirms that de-stocking is not turning into structural share loss.
• Take profits into any sharp rerating before visible China recovery arrives; the market can front-run normalization by 6-9 months, so the upside is meaningful but not linear.